Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 2
---
 Shares of Common Stock

Placement Agent Warrants to Purchase up to 210,420 Shares of Common Stock

Up to 17,745,490 Shares of Common Stock Issuable Upon Exercise of

Pre-Funded Warrants, Warrants and Placement Agent Warrants</div>

We are offering up to 7,014,028 shares (the “Shares”) of our common stock, par value $0.007 per share (the “Common Stock”), together with warrants to purchase up to 10,521,042 shares of Common Stock, which we refer to as the “April 2025 Warrants,” (such number of shares of Common Stock issuable upon exercise of the April 2025 Warrants equal to 150% of the number of Shares and Pre-Funded Warrants which does not include up to an additional 64,553,954 shares of Common Stock issuable upon the reset of the Warrants pursuant anti-dilution and reverse stock split adjustment provisions included therein as described in more detail below) pursuant to this prospectus. The assumed combined public offering price for each share of Common Stock and accompanying April 2025 Warrant to purchase one and one-half share of Common Stock is $0.499, which is equal to the last reported sale price of our Common Stock on the Nasdaq Capital Market (“Nasdaq” or the “Nasdaq Capital Market”) on April 25, 2025. Each share of our Common Stock is being sold together with one April 2025 Warrant to initially purchase one and one-half share of Common Stock. The April 2025 Warrants will have an initial exercise price of $[*] per share (110% of the combined public offering price per share of Common Stock and accompanying April 2025 Warrant) and will be exercisable beginning on the later of the effective date of the filing of an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to increase our authorized number of shares of Common Stock and the date of stockholder approval of the issuance of the shares upon exercise of the April 2025 Warrants (collectively, the “Warrant Stockholder Approval”). The April 2025 Warrants will expire on the five-year anniversary of the Warrant Stockholder Approval. The terms of the April 2025 Warrants will include (i) a one-time thirty percent increase in the number of shares of Common Stock issuable upon exercise of the April 2025 Warrants if a reverse stock split is effected